DUBLIN (Reuters) – Irish drugmaker Elan said it will give shareholders 20 percent of the royalty rights for multiple sclerosis drug Tysabri in a bid to stave off an approach for the company by U.S. investment firm Royalty Pharma .
Reuters article archive.
Visiting France? Get the best Paris deals at LinkParis.com before your trip.
Arrange a visit to see the D-Day landing beaches in Normandy, the castles of the Loire Valley, a Mont St. Michel tour, Paris Day Trips and more!
Get your NewsFlares.com now!
Email corrections to:
Send news tips to:
Write for us: